Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SCN1A | P35498 | 3/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | PTPRF | P10586 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976987 | 0.86 | MAPT (0.69) | MAPTCYP2C9CYP2C19POLBKMT2A | |
| SCHEMBL13616264 | 0.86 | MAPT (0.70) | MAPTCYP2C9CYP2C19POLBKMT2A | |
| SCHEMBL11977004 | 0.83 | MAPT (0.65) | MAPTCYP2C9CYP2C19POLBKMT2A | |
| SCHEMBL8621135 | 0.82 | MAPT (1.00) | MAPTCYP2C9CYP2C19POLBKMT2A | |
| SCHEMBL28316315 | 0.82 | MAPT (0.48) | MAPTCYP2C9CYP2C19POLBKMT2A | |
| SCHEMBL8551089 | 0.80 | CARM1 (0.57) | MAPTCYP2C19KMT2AMEN1ALDH1A1 | |
| SCHEMBL28631027 | 0.80 | HRH3 (0.47) | MAPTCYP2C9CYP2C19POLBKMT2A | |
| SCHEMBL578125 | 0.80 | ALDH1A1 (0.46) | MAPTCYP2C9CYP2C19POLBKMT2A | |
| Hydrochloric Acid SCHEMBL8554706 | 0.79 | KMT2A (0.58) | MAPTCYP2C19KMT2AMEN1ALDH1A1 | |
| SCHEMBL16669518 | 0.79 | NPY5R (0.45) | MAPTCYP2C9CYP2C19POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567041-B1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2023-12-27 | — | — | EP | disclosed |
| CN-110167941-B | Substituted fused heteroaryl compounds as kinase inhibitors and uses thereof | 上海瑛派药业有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3567041-A1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics, Inc (CN) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | MAPT 3592/4885CYP2C9 2331/4885CYP2C19 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.